Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The <i>in vivo</i> CAR-T paradigm shift-Reflections from Boston and the rise of programmable immunity.

Molecular therapy. Nucleic acids·2026
Same author

Magneto-electrochemical biosensing for pathogen detection using nuclease-responsive nanohybrids.

Mikrochimica acta·2026
Same author

Scaling the RNA Summit: Reflections on the 2026 OPT congress.

Molecular therapy. Nucleic acids·2026
Same author

The post-pandemic pivot: mRNA therapeutics enter the chronic rare disease arena.

Molecular therapy. Nucleic acids·2026
Same author

Advancing the science of nucleic acids together.

Molecular therapy. Nucleic acids·2026
Same author

Aroclor 1254 inhibits anti-inflammatory macrophage polarization through an AhR-dependent mechanism.

Journal of the Endocrine Society·2026

Related Experiment Video

Updated: May 9, 2026

Development of Cell-type specific anti-HIV gp120 aptamers for siRNA delivery
13:47

Development of Cell-type specific anti-HIV gp120 aptamers for siRNA delivery

Published on: June 23, 2011

Methods for Evaluating Cell-Specific, Cell-Internalizing RNA Aptamers.

Luiza I Hernandez1, Katie S Flenker, Frank J Hernandez

  • 1Department of Internal Medicine, University of Iowa, Iowa City, IA 52242, USA.

Pharmaceuticals (Basel, Switzerland)
|July 30, 2013
PubMed
Summary

Developing effective delivery methods for small interfering RNAs (siRNAs) is crucial. This study presents new methods to track aptamer-mediated cellular uptake and cytoplasmic delivery for targeted siRNA therapeutics.

Keywords:
RNA aptamerscell-SELEXcell-internalizing aptamerssiRNA deliverytargeted delivery

More Related Videos

Determination of In Vitro and Cellular Turn-on Kinetics for Fluorogenic RNA Aptamers
08:11

Determination of In Vitro and Cellular Turn-on Kinetics for Fluorogenic RNA Aptamers

Published on: August 9, 2022

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

Related Experiment Videos

Last Updated: May 9, 2026

Development of Cell-type specific anti-HIV gp120 aptamers for siRNA delivery
13:47

Development of Cell-type specific anti-HIV gp120 aptamers for siRNA delivery

Published on: June 23, 2011

Determination of In Vitro and Cellular Turn-on Kinetics for Fluorogenic RNA Aptamers
08:11

Determination of In Vitro and Cellular Turn-on Kinetics for Fluorogenic RNA Aptamers

Published on: August 9, 2022

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

Area of Science:

  • Biotechnology
  • Molecular Biology
  • Drug Delivery

Background:

  • Clinical trials of small interfering RNAs (siRNAs) necessitate advanced delivery systems for human therapeutic applications.
  • Cell targeting via conjugation to cell-specific ligands offers a promising strategy for siRNA delivery.
  • Synthetic RNA ligands, or aptamers, are emerging as potent tools for targeted therapeutic delivery.

Purpose of the Study:

  • To develop and validate methods for monitoring aptamer internalization and cytoplasmic delivery.
  • To facilitate the development of aptamer ligands for targeted delivery of therapeutic siRNAs in vivo.

Main Methods:

  • Cell-based selection approaches to isolate internalizing aptamers.
  • Antibody amplification microscopy for aptamer uptake visualization.
  • Microplate-based fluorescence assay for quantifying aptamer internalization.
  • Quantitative and Ultrasensitive Internalization Method (QUSIM) for precise uptake measurement.
  • Ribosome inactivating protein-based (RNA-RIP) assay to monitor cytoplasmic delivery.

Main Results:

  • Established methods effectively monitor aptamer cellular uptake and translocation to the cytoplasm.
  • The developed toolset supports the isolation of aptamers with desired internalization properties.
  • Demonstrated feasibility of using aptamers for targeted delivery of therapeutic siRNAs.

Conclusions:

  • The presented methods provide a comprehensive toolkit for expediting aptamer development.
  • These tools are essential for advancing aptamer-siRNA conjugate technology for in vivo applications.
  • Successful aptamer-mediated delivery is key to realizing the potential of siRNA therapeutics.